<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>CA Uyl‐de Groot on data_fR@</title>
    <link>/authors/ca-uylde-groot/</link>
    <description>Recent content in CA Uyl‐de Groot on data_fR@</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 14 Apr 2020 00:00:00 +0200</lastBuildDate>
    
	<atom:link href="/authors/ca-uylde-groot/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Cost-effectivness of CAR T-cell therapy for pALL. A societal view.</title>
      <link>/publication/cea-cart/</link>
      <pubDate>Tue, 14 Apr 2020 00:00:00 +0200</pubDate>
      
      <guid>/publication/cea-cart/</guid>
      <description>In this article we conduct a cost-utility analyses of the CAR T-cell therapy tisagenlecleucel from a health care perspective and societal perspective.</description>
    </item>
    
    <item>
      <title>Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model.</title>
      <link>/publication/gvhd-model/</link>
      <pubDate>Thu, 01 Nov 2018 00:00:00 +0200</pubDate>
      
      <guid>/publication/gvhd-model/</guid>
      <description>In this article we describe the development and simulation of a decision model for the second-line treatment of acute GvHD.</description>
    </item>
    
  </channel>
</rss>